The Zacks Analyst Blog Highlights: Target, Wal-Mart Stores,, Costco Wholesale and Quest Diagnostics

The Zacks Analyst Blog Highlights: Target, Wal-Mart Stores,, Costco
                       Wholesale and Quest Diagnostics

PR Newswire

CHICAGO, Oct. 23, 2012

CHICAGO, Oct. 23, 2012 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Target Corporation (NYSE:TGT),
Wal-Mart Stores Inc. (NYSE:WMT), Inc. (Nasdaq:AMZN), Costco
Wholesale Corporation (Nasdaq:COST) and Quest Diagnostics (NYSE:DGX).


Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter:

Here are highlights from Monday's Analyst Blog:

Target to Open More Stores

In an effort to further strengthen its operational roots, Target Corporation
(NYSE:TGT), the operator of general merchandise and food discount stores in
the United States, announced the opening of 3 new stores in Chicago, New York
and San Francisco.

The move reflects the company's strategic initiative to expand in regions
where it generates strong sales. Moreover, the San Francisco store is the
extension of its smaller-format stores called CityTarget.

Target Corporation, in order to tap the urban markets where real estate
remains a constraint, plans to introduce smaller-format stores called
CityTarget, similar to that of its biggest rival, Wal-Mart Stores Inc.

Earlier, the company unveiled its first three smaller format stores in Los
Angeles, Seattle and Chicago. We believe that the approach will help the
company to augment its sales by enhancing its accessibility to the country's
thickly populated urban regions and space-crunched cities.

The company has announced its plan to open 10 Target stores in 2013, which
includes the smaller format stores in Los Angeles, Portland and San Francisco.

Moreover, the company for the first time announced that it will allow its
shoppers to match the prices being offered by online retail giants. Consumers
will have the facility of compare prices being offered by Inc.
(Nasdaq:AMZN), Wal-Mart Stores Inc.'s, Best Buy Co. Inc.'s and

According to the price matching policy, the customer will not find any
discrepancy in pricing if an item is purchased between November 1^st and
December 24^th from Target stores. However, if the item costs less at or in a local competitor's printed ad, Target will provide items
matching the price.

Currently, we have a long-term 'Neutral' rating on the stock. However, the
company, which competes with Costco Wholesale Corporation (Nasdaq:COST), holds
a Zacks #2 Rank, which translates into a short-term 'Buy' rating.

DGX to Buy UMass Medical Center

Leading diagnostic tester Quest Diagnostics (NYSE:DGX) is keeping at par with
its Merger and Acquisition (M&A) strategy which the company expects to remain
as its key driver of growth. Recently as part of this strategy, the company
teamed up with Central New England's largest health care system UMass Memorial
Health Care to purchase its UMass Memorial Medical Center.

Although financial terms of this definitive purchase agreement were not
disclosed, Quest Diagnostics expects the transaction to be completed in the
next 3 months, subject to certain customary regulatory clearance. The
diagnostic testing stalwart expects the incorporation of UMass Memorial
Medical Center to add 1% to the company's consolidated revenues in the next
fiscal with no bottom-line impact. However, the company expects this
transaction to be accretive to its earnings per share (EPS) in fiscal 2014.

Quest Diagnostics expects this acquisition to establish a long-term
relationship between the two organizations. The plan states that Quest
Diagnostics' full-service laboratory in Cambridge and its Athena Diagnostics
specialty neurology testing subsidiary in Worcester will be moved to a
centrally located new facility in Massachusetts.

The company expects this facility, after being fully operational in next 18–24
months, to perform the testing currently performed at UMass Memorial's
Worcester-based outreach laboratories as well as Quest Diagnostics' Cambridge
and Athena.

Per the plan, UMass Memorial will be taking a financial stake in the new
entity that would develop and operate a leading-edge laboratory in
Massachusetts in the future. Both the organizations expect this advanced
laboratory service to include a number of benefits like higher quality
service, expanded information connectivity options, and reduced laboratory
testing costs.

Quest Diagnostic believes that the impending acquisition is in sync with its
goal to create the company's planned 'lab of the future' which will help it
increase long-term growth opportunities and increase shareholders' value.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.